ADC Therapeutics SA (ADCT)
NYSE: ADCT · Real-Time Price · USD
1.590
+0.170 (11.97%)
At close: Oct 8, 2026, 4:00 PM EDT
1.584
-0.006 (-0.38%)
After-hours: Oct 8, 2026, 7:59 PM EDT
ADC Therapeutics Revenue
ADC Therapeutics had revenue of $19.25M in the quarter ending June 30, 2026, with 2.17% growth. This brings the company's revenue in the last twelve months to $79.58M, up 3.03% year-over-year. In the year 2025, ADC Therapeutics had annual revenue of $81.36M with 14.85% growth. That makes ADC Therapeutics the 24,389th largest company in the world by revenue and 3,452nd in the United States.
Revenue (ttm)
$79.58M
Revenue Growth
+3.03%
P/S Ratio
2.55
Revenue / Employee
$412,352
Employees
193
Market Cap
202.99M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 81.36M | 10.52M | 14.85% |
| Dec 31, 2024 | 70.84M | 1.28M | 1.84% |
| Dec 31, 2023 | 69.56M | -140.35M | -66.86% |
| Dec 31, 2022 | 209.91M | 175.99M | 518.89% |
| Dec 31, 2021 | 33.92M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Organogenesis Holdings | 457.45M |
| Aurora Cannabis | 221.16M |
| Akebia Therapeutics | 219.06M |
| Organigram Global | 217.71M |
| Lifecore Biomedical | 129.46M |
| Anika Therapeutics | 120.65M |
| Journey Medical | 68.18M |
| SIGA Technologies | 53.66M |
ADCT News
- 14 hours ago - ADC Therapeutics announces comprehensive strategic financial restructuring - TheFly
- 14 hours ago - ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements - PRNewsWire
- 17 days ago - These beaten-down stocks could bounce back in January, if history is any guide - Market Watch
- 27 days ago - ADC Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 27 days ago - ADC Therapeutics Slides: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Filings
- 5 weeks ago - ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference - PRNewsWire
- 7 weeks ago - ADC Therapeutics price target lowered to $5 from $10 at Guggenheim - TheFly
- 7 weeks ago - ADC Therapeutics reports Q2 adjusted EPS (11c) vs. (25c) last year - TheFly